Month: March 2026

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 10:00 a.m. ET in Miami, FL. The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webcast will be available on the Lexeo website following the presentation. About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing...

Vancouver, BC, March 03, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X45) (“Deep Sea Minerals” or the “Company”), a subsea mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, is pleased to announce the initiation of engagement with the National Oceanic and Atmospheric Administration (“NOAA”) in connection with the Company’s intention to advance deep seabed mineral resource development under the applicable U.S. regulatory framework. The initiation of this process represents an important procedural step in Deep Sea Minerals’ planned advancement through the U.S. jurisdictional process. The Company intends to proceed with the submission of a comprehensive application in accordance with NOAA’s regulatory requirements. “This...

HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17th. A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET that day. Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. About Harvard Bioscience  Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing...

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the Citizens Life Sciences Conference on Tuesday, March 10th, 2026 at 11:55 AM (ET). About Anavex Life Sciences Corp. Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric...

Fourth quarter net sales totaled $160.4 million, up 25.1% over last year with increases of 23.7% in Rail and 27.3% in Infrastructure, both driven by strong improvements in North American demand. Fourth quarter net income of $2.4 million was favorable $2.6 million versus last year; Adjusted EBITDA1 of $13.7 million increased $6.4 million, or 89.0%, versus last year; Selling and administrative expenses as a percentage of sales were 14.4% for the quarter, favorable 470 bps versus last year. Full year 2025 cash flow from operations was $35.6 million, with $22.2 million generated in the fourth quarter; operating cash flow was used to reduce total debt by $16.0 million during the quarter to $42.8 million, with Gross Leverage Ratio1 at 1.0x at year end compared to 1.2x last year. The Company announced 2026 financial guidance with net sales...

JOHNS CREEK, Ga., March 03, 2026 (GLOBE NEWSWIRE) — Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, is providing LTL shipment and tonnage data for the first two months of the first quarter. In January 2026, LTL shipments per workday declined 2.1%, LTL tonnage per workday declined 7.0% and LTL weight per shipment declined 5.1%, in each case compared to January 2025. In February 2026, LTL shipments per workday increased 0.3%, LTL tonnage per workday declined 2.7% and LTL weight per shipment declined 3.0%, in each case compared to February 2025. Additionally, contractual renewals in January 2026 were 6.6% and remained strong in February 2026 at 5.9%. These changes are summarized in the table below:    January 2026 versus...

CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona’s website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available for 30 days following the call. Participation in 2026 Leerink Global Healthcare Conference Abeona management will participate...

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) — Lahontan Gold Corp. (TSXV:LG, OTCQB:LGCXF, FSE:Y2F) (the “Company” or “Lahontan“) is pleased to announce that it has mobilized a track-mounted reverse-circulation (“RVC”) drill rig and crew to its Flagship Santa Fe Mine project in Nevada’s gold and silver-rich Walker Lane. The MPD-1500 RVC track-mounted drill rig will augment the diamond drill rig currently operating at Santa Fe with a focus on drilling areas of the project that have seen little or no exploration drilling. Kimberly Ann, Lahontan Executive Chair, President, CEO, and Founder commented: “Since the Company’s inception, Lahontan drilling has focused on resource definition and expansion to support our goal of resuming gold and silver production and mining operations at Santa Fe. With the approval of our...

Company Exec. Chairman & CEO in a fireside chat is expected to highlight the role of Skinject in an autosomal dominant rare disease, AI-enabled drug development strategy and partnering readiness PHILADELPHIA, March 03, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will be participating in the 38th Annual Roth Conference, being held March 22-24, 2026, in Dana Point, California. Dr. Raza Bokhari, Executive Chairman & CEO of Medicus, will participate in a Fireside Chat hosted by Roth Capital Partners Managing Director and Senior Research Analyst Jonathan Aschoff. Dr. Bokhari will review the...

Total holdings of approximately 70.4 million units of BERA as of February 27, 2026 Up to 50 million units of BERA deployed into validator infrastructure across multiple operators Jason Hitchcock appointed Chief Executive Officer to advance DAT strategy BOCA RATON, Fla., March 03, 2026 (GLOBE NEWSWIRE) — Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq: GNLN), a company with a Berachain-focused Digital Asset Treasury (“DAT”), is providing an update on its holdings of units of BERA and deployment activity. Digital Asset Treasury Holdings Update As of February 27, 2026, the Company held approximately 70.4 million units of BERA1. Since the Company’s last treasury update on December 8, 2025, the following developments have occurred: BERA Purchases: Between December 4, 2025 and February 27, 2026, the Company acquired...